You need to enable JavaScript in order to use the AI chatbot tool powered by ChatBot

Resources

Webinars

Our free webinars offer the latest ideas and insights from life sciences experts at LifeNet Health and beyond. Explore the options below. Topics include primary human hepatocytes, biospecimens, hepatic in vitro systems, cytotoxicity testing, 3D thyroid microtissue, liver non-parenchymal cells, and more.

 

  • Nov
    Innovative Approaches to Assessing Thyroid Disruption

    Join US EPA Cell Biologist Chad Deisenroth, PhD, and LifeNet Health LifeSciences as they unveil a revolutionary human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption.

    Key Learnings:

    • The need for a 3D human thyroid microtissue model to address current challenges with existing models.
    • The importance of the model to screen chemicals for potential thyroid-disrupting effects.
    • The methodology behind model standardization and validation.
    Duration:
    1 hr with live Q&A

Recorded Webinars

Browse our collection of previously recorded webinars

  • TruVivo is a Promising New Tool for Toxicity Testing

    Edward LeCluyse, PhD, Chief Scientist for LifeNet Health LifeSciences, will share the latest insights for how TruVivo can serve as a promising new tool for toxicity testing. 

    Key learnings will be:

    • How CYP and UGT enzymatic activity and transporter uptake in TruVivo remains functional and stable for greater than 14 days.
    • How TruVivo accurately ranks the toxicity of several reference compounds representing multiple mechanisms of action.
    • How the addition of human Kupffer cells in the TruVivo system successfully captures inflammatory and fibrogenic responses that lead to enhanced compound toxicity.
  • Human Biospecimens Unveiled: Navigating Cutting-Edge Standards for Research

    Bud Brame and Jeff Thomas, from LifeNet Health LifeSciences discuss how LifeNet Health ensures the highest standards in the recovery, transport, and handling of human biospecimens for research and how these critical steps are essential to the quality of tissue used in pre-clinical research studies and greatly impacts the quality of data generated.

  • Cell Selection for In Vitro Applications: Maximizing Translational Success

    Sharon Presnell, PhD, LifeNet Health LifeSciences Vice President of Product Development, discusses the dynamic landscape of biomedical research and how choosing the right cells for your experiment is a fundamental step in achieving meaningful and reproducible results. Careful consideration is vital to success, whether your work involves drug discovery, disease modeling, cytotoxicity assays, or studying cellular processes.

  • Evaluation of TruVivo, an All-Human Hepatocyte Model, for Mechanistic DMPK Investigations

    Diane Ramsden, PhD, from AstraZeneca, presents data from her evaluation of TruVivo as a potential tool for investigating mechanistic DMPK, including drug-drug interaction potential and translational risk assessment.

  • Unveiling New Insights: The Latest Application Data from TruVivo

    Ed LeCluyse, PhD, Chief Scientist LifeNet Health LifeSciences, reveals application data generated by leading pharmaceutical partners, demonstrating the use of TruVivo for ADME/DMPK and disease modeling applications. Dr LeCluyse also shares a sneak peek of where TruVivo stands regarding the inclusion of human Kupffer cells and preclinical species.

  • Developing an In Vitro Integrated Organ Model for Pharmacokinetic and ADME Predictions

    Emerging toxicology methods can help researchers move away from traditional animal testing. Industry leader James McKim, PhD, will provide information about how to select the best platform – including the need for integrated organ models. 

  • Human Hepatocyte Tri-Culture System: A Convenient 3-in-1 Model for In Vitro Hepatic Assays

    Ed LeCluyse, PhD, LifeNet Health LifeSciences, reveals the convenient all-human hepatocyte triculture model, highlighting improvements in hepatocyte performance compared to traditional monoculture.

  • A Novel, All-Human Hepatic Triculture System

    Ed LeCluyse, PhD, and Paul Gallant, BA, of LifeNet Health provide an inside look at a novel all-human hepatic triculture system developed by LifeNet Health LifeSciences.

  • All-Human Hepatic Tri-Culture System

    Jessica Weaver, PhD, Research and Product Development Scientist at LifeNet Health, reviews data from our new hepatic cell-based co-culture model which is comprised of primary human hepatocytes with human feeder cells, all derived 100% from donated human tissue. 

  • Explore New Frontiers in Multi-Organ Microphysiological Systems

    Learn about how multi-organ microphysiological systems are being used as an investigative tool in medical research as Martin Trapecar, PhD, explains his work to investigate the fundamental origins of immunometabolic diseases.

  • A Skin-Liver-Thyroid MPS Model: Cosmetics Europe LRSS Case Study Webinar

    Nicky Hewitt, PhD, a consultant with Cosmetics Europe, explains how her skin-liver-thyroid MPS model is being used to support animal-free cosmetics testing.

  • Use of Human Liver Cells in 3D Microphysiology System

    Microphysiology systems offer promising new alternatives for disease investigations and safety testing. Learn more about this leading-edge technology in our webinar featuring Lawrence Vernetti, PhD, of the University of Pittsburgh.

  • New Approach Method: In Vitro 3D Human Thyroid Model

    Eda Rogers, PhD, A Research & Discovery Scientist at LifeNet Health, shares her research into a new approach using an in vitro 3D human thyroid model. This project, under development with the United States Environmental Protection Agency, represents the first human thyroid model system to be considered for the Endocrine Disruptor Screening Program.

  • Merging Systems Biology with Tissue Engineering and Organs on Chips

    Learn about the latest efforts to gain insight into human diseases using microphysiological systems, featuring Linda Griffith, PhD.

  • Genotypes of Primary Human Hepatocytes: Predictability and Considerations

    Mary Jane Cunningham, PhD, LifeNet Health LifeSciences Director for Clinical Applications and Services, discusses how the genotype for primary human hepatocytes may be essential to your research and testing.

  • Human Liver Cells for Transplantation

    Chandan Guha, PhD, of the Albert Einstein College of Medicine presents his research focusing on the adverse effects of irradiation on normal tissue.

  • Access to Human Biospecimens for Research

    Program Director Jeffrey Thomas describes the industry-leading recovery protocols and enhanced donor family consent process he helped develop for LifeNet Health LifeSciences.

  • Primary Human Hepatocytes in Drug Development: Challenges and Opportunities Part 1

    Donald Tweedie, PhD, and Edward LeCluyse, PhD, share lessons learned over a combined 70 years in drug development and research on alternative drug metabolism and toxicological methods.

  • Primary Human Hepatocytes in Drug Development: Challenges and Opportunities Part 2

    Donald Tweedie, PhD and Ed LeCluyse, PhD continue their former discussion on the challenges and opportunities with using primary human hepatocytes in drug development. 

  • LifeNet Health LifeSciences: Your New Partner in Drug Discovery and Development

    Ed LeCluyse, PhD, explains how LifeNet Health LifeSciences' unique, vertically integrated process has raised the bar for quality standards to enable access to high-quality human tissues and cells for research.

  • Characterizing the "Invisible Wound" of Military Traumatic Brain Injury

    Daniel Perl, PhD, presents his research aimed at understanding the long-term consequences of traumatic brain injury (TBI) among military personnel. Dr. Perl is the Director of the Brain Tissue Repository at the Uniformed Services University of the Health Sciences/Department of Defense in Bethesda, Md.

  • To the Moon and Back! Maintaining Integrity of Human Biospecimens

    Scott Jewel, PhD, and Galen Hostetter, PhD, both of the Van Andel Research Institute, share their best practices for the management and use of biospecimens, specifically around the identification of variables on biospecimen quality and processing that can directly impact research results.

  • Cryopreserved Primary Human Thyrocytes for Thyroid Disruptive Chemical Screening

    Eda Rogers, PhD, Research and Development Scientist at LifeNet Health, shares details of how she and other LifeNet Health scientists have isolated, cryopreserved, and characterized primary human thyrocytes,

  • Considerations for Tissue Donation Authorization - the GTEx Case Study

    Laura Siminoff, PhD, Dean at the College of Public Health at Temple University, discusses best practices for communicating and obtaining consent from donor families based on experience from the Genotyping-Tissue Expression Project (GTEx).

  • Biospecimen Research on Earth and in Space: A Model for Human Osteoarthritis in the Space Shuttle

    Alan Grodzinsky, ScD, of the Massachusetts Institute of Technology shares exciting details on a human, in vitro model being co-developed by MIT, the NIH National Center for Advancing Translational Sciences, and the National Aeronautics and Space Administration.

  • Utilizing Human Hepatocyte Genotyping Data to Optimize Experimental Design

    Mary Jane Cunningham, PhD, explains how the genotyping of primary human hepatocytes may be essential to your experimental design and how knowing the donor’s genotype could help with stratifying hepatocyte lots used in drug discovery and development assays.

  • Accelerating Drug Discovery and Development with Primary Human Hepatocytes

    Ed LeCluyse, PhD, Chief Scientist of LifeNet Health’s Institute of Regenerative Medicine, presents on the criticality of utilizing primary human hepatocytes in pre-clinical drug development.

  • 3D Models of Microtumors – A New Predictive Tool?

    Chris Willey, MD, PhD, shares how 3D human microtumors are being established as a human-based diagnostic screening method to optimize chemotherapeutic regimens.

  • Biospecimens for Research: Accelerating Access and Ensuring Quality

    Only LifeNet Health LifeSciences controls every step of a tissue's journey from donor to lab while serving researchers needs from early-stage discovery to pre-clinical drug-safety evaluation.

  • Human Liver Non-Parenchymal Cells: Award Winning Actors in Liver Disease

    Ed LeCluyse, PhD, Chief Scientist of LifeNet Health’s Institute of Regenerative Medicine, describes how liver non-parenchymal cells (NPCs) — including stellate, Kupffer, and liver endothelial cells — play a role in the progression of liver toxicity and disease.

  • Understanding Primary Human Hepatocyte Characterization Data

    Dr. Ed LeCluyse from LifeNet Health LifeSciences describes the importance of using data to identify the right hepatocyte lots for your specific applications, with insight into emerging trends in hepatocyte characterization.